Your browser doesn't support javascript.
loading
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.
Lemaitre, Florian; Solas, Caroline; Grégoire, Matthieu; Lagarce, Laurence; Elens, Laure; Polard, Elisabeth; Saint-Salvi, Béatrice; Sommet, Agnès; Tod, Michel; Barin-Le Guellec, Chantal.
Afiliação
  • Lemaitre F; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000, France.
  • Solas C; INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, F-35000, France.
  • Grégoire M; Aix-Marseille University, APHM, UMR "Emergence des Pathologies Virales" Inserm 1207 IRD 190, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, Marseille, 13005, France.
  • Lagarce L; Clinical Pharmacology Department, CHU Nantes, Nantes Cedex 1, Nantes, 44093, France.
  • Elens L; UMR INSERM 1235, The Enteric Nervous System in Gut and Brain Disorders, University of Nantes, Nantes Cedex 1, Nantes, 44093, France.
  • Polard E; Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d'Angers, Angers, 49100, France.
  • Saint-Salvi B; Integrated Pharmacometrics, Pharmacogenomics and Pharmacokinetics (PMGK), Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCL), Louvain, Belgique.
  • Sommet A; Louvain Center for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCL), Louvain, Belgique.
  • Tod M; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000, France.
  • Barin-Le Guellec C; INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, F-35000, France.
Fundam Clin Pharmacol ; 34(5): 530-547, 2020 Oct.
Article em En | MEDLINE | ID: mdl-32603486
Patients with COVID-19 are sometimes already being treated for one or more other chronic conditions, especially if they are elderly. Introducing a treatment against COVID-19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug-drug interactions. Here, we analyzed the potential or proven risk of the co-administration of drugs used for the most common chronic diseases and those currently offered as treatment or undergoing therapeutic trials for COVID-19. Practical recommendations are offered, where possible.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Infecções por Coronavirus / Medicamentos sob Prescrição Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Limite: Humans Idioma: En Revista: Fundam Clin Pharmacol Assunto da revista: FARMACOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Infecções por Coronavirus / Medicamentos sob Prescrição Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Limite: Humans Idioma: En Revista: Fundam Clin Pharmacol Assunto da revista: FARMACOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França País de publicação: Reino Unido